Sysmex (OTCMKTS:SSMXY) Reaches New 52-Week Low - Should You Sell?

Key Points

• Sysmex Corporation shares hit a new 52-week low at $12.47, closing slightly higher at $12.96 with trading volume of 2,825 shares.
• The company recently reported a quarterly EPS of $0.05, missing the expected $0.12, alongside revenue of $717.09 million, which was below the anticipated $807.27 million.
• Zacks Research upgraded Sysmex's rating from "strong sell" to "hold," reflecting a cautious outlook with a current consensus rating also at "hold."

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $12.47 and last traded at $12.96, with a volume of 2825 shares changing hands. The stock had previously closed at $12.92.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Sysmex from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of "Hold".

Sysmex Stock Performance

The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.49 and a current ratio of 3.37. The firm has a market cap of $8.03 billion, a P/E ratio of 25.52 and a beta of 1.10. The business's 50-day simple moving average is $14.77 and its 200 day simple moving average is $16.81.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.07). Sysmex had a return on equity of 10.20% and a net margin of 9.35%.The company had revenue of $717.09 million during the quarter, compared to the consensus estimate of $807.27 million. As a group, equities analysts predict that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.